# AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer

> **NCT02053324** · PHASE1 · TERMINATED · sponsor: **Alfasigma S.p.A.** · enrollment: 14 (actual)

## Conditions studied

- Liver Metastases

## Interventions

- **COMBINATION_PRODUCT:** AvidinOX/ST2210

## Key facts

- **NCT ID:** NCT02053324
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-11
- **Primary completion:** 2019-06-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Low recruitment rate
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053324, "AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02053324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*